State of Alaska Department of Revenue acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 6,400 shares of the company’s stock, valued at approximately $496,000.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in NBIX. Teachers Advisors LLC grew its position in Neurocrine Biosciences by 10.8% in the second quarter. Teachers Advisors LLC now owns 91,550 shares of the company’s stock valued at $4,211,000 after acquiring an additional 8,903 shares during the period. New York State Common Retirement Fund boosted its stake in Neurocrine Biosciences by 34.1% in the second quarter. New York State Common Retirement Fund now owns 255,401 shares of the company’s stock worth $11,748,000 after purchasing an additional 65,005 shares in the last quarter. Northern Trust Corp boosted its stake in Neurocrine Biosciences by 0.8% in the second quarter. Northern Trust Corp now owns 475,963 shares of the company’s stock worth $21,894,000 after purchasing an additional 3,887 shares in the last quarter. Vanguard Group Inc. boosted its stake in Neurocrine Biosciences by 2.8% in the second quarter. Vanguard Group Inc. now owns 6,922,294 shares of the company’s stock worth $318,426,000 after purchasing an additional 186,329 shares in the last quarter. Finally, California Public Employees Retirement System boosted its stake in Neurocrine Biosciences by 2.2% in the second quarter. California Public Employees Retirement System now owns 179,300 shares of the company’s stock worth $8,248,000 after purchasing an additional 3,900 shares in the last quarter.
In other news, insider Darin Lippoldt sold 9,900 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $73.05, for a total value of $723,195.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Gary A. Lyons sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $72.92, for a total value of $729,200.00. Following the completion of the transaction, the director now directly owns 272,066 shares of the company’s stock, valued at $19,839,052.72. The disclosure for this sale can be found here. Insiders have sold a total of 189,707 shares of company stock worth $14,975,715 over the last ninety days. Company insiders own 4.80% of the company’s stock.
Shares of Neurocrine Biosciences, Inc. (NBIX) traded up $0.71 on Friday, reaching $79.28. The company’s stock had a trading volume of 893,670 shares, compared to its average volume of 961,879. The firm has a market cap of $7,015.72, a P/E ratio of -35.71, a PEG ratio of 13.14 and a beta of 0.26. Neurocrine Biosciences, Inc. has a 52-week low of $39.21 and a 52-week high of $91.82. The company has a debt-to-equity ratio of 1.05, a current ratio of 14.38 and a quick ratio of 14.37.
NBIX has been the subject of a number of recent analyst reports. BidaskClub upgraded Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Wednesday, January 31st. Needham & Company LLC increased their price target on Neurocrine Biosciences to $95.00 and gave the stock a “buy” rating in a report on Tuesday, January 16th. Oppenheimer set a $95.00 price target on Neurocrine Biosciences and gave the stock a “buy” rating in a report on Monday, January 15th. Jefferies Group increased their price objective on Neurocrine Biosciences to $105.00 and gave the stock a “buy” rating in a report on Friday, January 5th. Finally, Robert W. Baird reiterated a “buy” rating and set a $84.00 price objective on shares of Neurocrine Biosciences in a report on Friday, November 3rd. One research analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $84.13.
COPYRIGHT VIOLATION NOTICE: “State of Alaska Department of Revenue Acquires New Position in Neurocrine Biosciences, Inc. (NBIX)” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://ledgergazette.com/2018/02/11/state-of-alaska-department-of-revenue-takes-496000-position-in-neurocrine-biosciences-inc-nbix.html.
Neurocrine Biosciences Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.